DrugPatentWatch Database Preview
CLEOCIN Drug Profile
When do Cleocin patents expire, and when can generic versions of Cleocin launch?
This drug has twenty-four patent family members in twenty-two countries.
The generic ingredient in CLEOCIN is clindamycin palmitate hydrochloride. There are fifty-five drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the clindamycin palmitate hydrochloride profile page.
Summary for CLEOCIN
| International Patents: | 24 |
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 14 |
| Suppliers / Packagers: | 3 |
| Bulk Api Vendors: | 63 |
| Clinical Trials: | 7 |
| Patent Applications: | 1,070 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | see details |
| DailyMed Link: | CLEOCIN at DailyMed |
Pharmacology for CLEOCIN
| Ingredient-type | Lincosamides |
| Drug Class | Lincosamide Antibacterial |
| Physiological Effect | Decreased Sebaceous Gland Activity |
Synonyms for CLEOCIN
| [(2R,3R,4S,5R,6R)-6-[(1S,2S)-2-chloro-1-[[(2S,4R)-1-methyl-4-propylpyrrolidine-2-carbonyl]amino]propyl]-4,5-dihydroxy-2-methylsulfanyloxan-3-yl] hexadecanoate;hydrochloride |
| [(2R,4S,5R)-6-[2-chloro-1-[[(2S,4R)-1-methyl-4-propylpyrrolidine-2-carbonyl]amino]propyl]-4,5-dihydroxy-2-methylsulfanyloxan-3-yl] hexadecanoate hydrochloride |
| [6-[2-chloro-1-[(1-methyl-4-propyl-pyrrolidine-2-carbonyl)amino]propyl]-4,5-dihydroxy-2-methylsulfanyl-tetrahydropyran-3-yl] hexadecanoate hydrochloride |
| 25507-04-4 |
| 34850-73-2 |
| 35208-55-0 (Parent) |
| 6-{2-chloro-1-[(1-methyl-4-propylpyrrolidin-2-yl)formamido]propyl}-4,5-dihydroxy-2-(methylsulfanyl)oxan-3-yl hexadecanoate hydrochloride |
| AB2000687 |
| AB51459 |
| AC-8823 |
| AC1L1OVK |
| AKOS015963324 |
| AKOS030242182 |
| AN-7626 |
| C-23416 |
| C34H63ClN2O6S.HCl |
| C34H64Cl2N2O6S |
| CAS-25507-04-4 |
| CHEBI:34647 |
| CHEMBL1200632 |
| Cleocin Pediatric |
| Cleocin pediatric (TN) |
| CLINDALYCIN PALMITATE HYDROCHLORIDE |
| Clindamycin 2-palmitate hydrochloride |
| Clindamycin palmitate HCl |
| CLINDAMYCIN PALMITATE HYDROCHLORIDE |
| Clindamycin palmitate hydrochloride (JAN/USP) |
| Clindamycin Palmitate Hydrochloride [USAN:JAN] |
| Clindamycin palmitate hydrochloride [USAN:USP:JAN] |
| Clindamycinpalmitatehydrochloride |
| CTK8F8720 |
| D01990 |
| DSSTox_CID_28660 |
| DSSTox_GSID_48734 |
| DSSTox_RID_82930 |
| DTXSID3048734 |
| J-016026 |
| L-threo-alpha-D-galacto-Octopyranoside, methyl 7-chloro-6,7,8-trideoxy-6-(((1-methyl-4-propyl-2-pyrrolidinyl)carbonyl)amino)-1-thio-2-hexadecanoate, monohydrochloride, (2S-trans)- |
| L-THREO-ALPHA-D-GALACTO-OCTOPYRANOSIDE, METHYL 7-CHLORO-6,7,8-TRIDEOXY-6-[[(1-METHYL-4-PROPYL-2-PYRROLIDINYL)CARBONYL]AMINO]-1-THIO-,2-HEXADECANOATE, MONOHYDROCHLORIDE, (2S-TRANS)- |
| LS-174102 |
| METHYL 7-CHLORO-6,7,8-TRIDEOXY-6-(1-METHYL-TRANS-4-PROPYL-L-2-PYRROLIDINECARBOXAMIDO)-1-THIO-L-THREO-ALPHA-D-GALACTO-OCTOPYRANOSIDE 2-HEXADECANOATE MONOHYDROCHLORIDE |
| Methyl 7-chloro-6,7,8-trideoxy-6-(1-methyl-trans-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-L-threo-alpha-D-galacto-octopyranoside 2-palmitate monohydrochloride |
| MolPort-003-983-293 |
| MolPort-028-599-793 |
| NCGC00185773-02 |
| NSC-759141 |
| NSC759141 |
| O721 |
| Pharmakon1600-01505470 |
| s2596 |
| SCHEMBL41416 |
| Tox21_113175 |
| U 25179E |
| U-25,179 E |
| UNII-VN9A8JM7M7 |
| VN9A8JM7M7 |
US Patents and Regulatory Information for CLEOCIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmacia And Upjohn | CLEOCIN | clindamycin hydrochloride | CAPSULE;ORAL | 061809-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
| Pharmacia And Upjohn | CLEOCIN T | clindamycin phosphate | GEL;TOPICAL | 050615-001 | Jan 7, 1987 | AB | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | |||
| Pharmacia And Upjohn | CLEOCIN | clindamycin phosphate | SUPPOSITORY;VAGINAL | 050767-001 | Aug 13, 1999 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | Y | ➤ Try a Free Trial | |||
| Pharmacia And Upjohn | CLEOCIN | clindamycin phosphate | CREAM;VAGINAL | 050680-002 | Mar 2, 1998 | AB | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | |||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
International Patents for CLEOCIN
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Morocco | 26749 | ➤ Try a Free Trial |
| China | 1360495 | ➤ Try a Free Trial |
| Slovenia | 1200065 | ➤ Try a Free Trial |
| European Patent Office | 1200065 | ➤ Try a Free Trial |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for CLEOCIN
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 00617 | Netherlands | ➤ Try a Free Trial | PRODUCT NAME: COMBINATIE VAN CLINDAMYCINE, DESGEWENST IN DE VORM VAN CLINDAMYCINEFOSFAAT EN TRETINOINE; NAT. REGISTRATION NO/DATE: RVG 109745 20130626; FIRST REGISTRATION: PA1332/043/001 20130322 |
| 13/044 | Ireland | ➤ Try a Free Trial | PRODUCT NAME: CLINDAMYCIN AND TRETINOIN; REGISTRATION NO/DATE: PA1332/043/001 20130322 |
| 1304992/01 | Switzerland | ➤ Try a Free Trial | PRODUCT NAME: CLINDAMYCINI PHOSPHAS ET TRETINOINUM; REGISTRATION NO/DATE: SWISSMEDIC 62513 28.03.2014 |
| 401 | Luxembourg | ➤ Try a Free Trial | PRODUCT NAME: CLINDAMYCINE(EN TANT QUE PHOPSHATE DE CLINDAMYCINE)ET TRETINOINE |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
